XVIVO Reports Strong Early Trial Results for HOPE Technology in DCD Heart Transplants

Xvivo Perfusion AB ( (SE:XVIVO) ) has shared an announcement.

XVIVO Perfusion AB reported encouraging interim results from the HOPE-at-Heart clinical trial, the first prospective multicenter study to test direct procurement of donor hearts after circulatory death followed by hypothermic oxygenated perfusion using the XVIVO Heart Assist Transport system. The single-arm proof-of-concept trial enrolled 40 adult recipients at four European centers and achieved 98% patient survival at 30 days, with low rates of severe primary graft dysfunction and post-operative mechanical circulatory support despite average preservation times exceeding 300 minutes.

Clinicians involved in the study highlighted the high utilization rate and strong early performance of DCD hearts preserved with HOPE, noting that the technique offers additional logistical flexibility that can help ensure more organs are used rather than discarded. XVIVO’s management said the findings add to a growing body of global clinical experience with HOPE in heart transplantation and support the company’s mission to help transplant programs expand access to donor organs, though the heart technology remains investigational and is not yet commercially available in the U.S.

The most recent analyst rating on (SE:XVIVO) stock is a Buy with a SEK225.00 price target. To see the full list of analyst forecasts on Xvivo Perfusion AB stock, see the SE:XVIVO Stock Forecast page.

More about Xvivo Perfusion AB

XVIVO Perfusion AB is a Swedish medical technology company focused on extending the life of major organs to enable more successful transplants. Its organ preservation and perfusion solutions are used by transplant teams and researchers globally, and the company is listed on Nasdaq Stockholm under the ticker XVIVO.

Average Trading Volume: 151,164

Technical Sentiment Signal: Buy

Current Market Cap: SEK9.37B

See more data about XVIVO stock on TipRanks’ Stock Analysis page.